Mersana Therapeutics said on Thursday the U.S. Food and Drug Administration (FDA) had paused enrollment in two studies of its ovarian cancer drug after five deaths in bleeding-related events, sending shares of the company tumbling.
A day after a federal judge blocked Texas' near-total abortion ban, at least one provider in the state said it had resumed services on Thursday for patients seeking to terminate pregnancies beyond the law's limit of about six weeks.